Navigation Links
Age, Other Illnesses May Make Prostate Cancer Treatment Unnecessary
Date:5/21/2013

TUESDAY, May 21 (HealthDay News) -- Aggressive treatment for prostate cancer may not be warranted for many older patients with underlying medical conditions, a new study finds.

Treatments for prostate cancer, such as surgery, radiation and radioactive seed implants, can cause serious side effects, such as erectile dysfunction, urinary incontinence and bowel problems, explained researchers from the University of California, Los Angeles (UCLA).

They found that older patients with slower growing forms of prostate cancer who have at least three other health problems are more likely to die of something other than cancer. The findings might help educate patients on the risks and benefits of treatment, the team said.

"For men with low- to intermediate-risk disease, prostate cancer is an indolent [slow-growing] disease that doesn't pose a major risk to survival," study author Timothy Daskivich said in a university news release. "The take home point from this study is that older men with multiple underlying health problems should carefully consider whether they should treat these tumors aggressively, because that treatment comes with a price," said Daskivich, who is Robert Wood Johnson fellow at UCLA.

In the study, the researchers analyzed the 14-year survival outcomes of 3,000 men diagnosed with prostate cancer between 1994 and 1995. Within six months of their diagnosis, the men completed surveys to document any other medical conditions they had.

Daskivich's team focused on older patients with three or more underlying health problems, such as diabetes, hypertension, congestive heart failure and/or arthritis.

They found the 10-year risk of dying from something other than prostate cancer for men aged 61 to 74 was 40 percent, and the 14-year risk of dying from low or intermediate risk prostate cancer was only 3 percent.

For men older than 75, the 10-year risk of dying from something other than cancer was 71 percent and their 14-year risk of dying from prostate cancer was only 7 percent.

"This was a great opportunity to get a glimpse at the long-term outcomes of these men diagnosed with prostate cancer in the mid-1990s," Daskivich said, and "the risk of dying from their cancer paled in comparison to the risk that they'd die from something else."

His advice: "If you're very unlikely to benefit from treatment, then don't run the risk and end up dealing with side effects that can significantly impact quality of life. It's important for these men to talk to their doctors about the possibility of forgoing aggressive treatment. We're not talking about restricting care, but the patient should be fully informed about their likelihood of surviving long enough to benefit from treatment."

The study authors pointed out it may take eight to 10 years for the survival benefits of treatment to emerge. In many cases, they said, closely monitoring prostate cancer is better than treating the disease as aggressively as possible.

The researchers noted however that men with high-risk forms of prostate cancer may still benefit from aggressive treatment. The study found that older men's 14-year risk of death from high-risk prostate cancer was 18 percent.

According to the U.S. National Cancer Institute, in 2013 nearly 240,000 American men are expected to develop prostate cancer.

The study was published online on May 21 in Annals of Internal Medicine.

More information

The U.S. National Cancer Institute provides more information on prostate cancer.

-- Mary Elizabeth Dallas

SOURCE: University of California, Los Angeles, news release, May 20, 2013.


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New insights into when beach sand may become unsafe for digging and other contact
2. Chemotherapy proves life-saving for some leukemia patients who fail induction therapy
3. Immunotherapy for elderly cancer patients finds new promise in drug combination
4. Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients
5. Concerns about MRSA for expectant mothers may be unfounded
6. Another Drug Take-Back Day Scheduled for Saturday
7. Low-Income Mothers May Overfeed Their Infants
8. New global report says US lags behind 130 other nations in preterm birth rate
9. Screening for Other Health Problems May Aid COPD Survival
10. Stem cell sparing radiotherapy for head and neck cancer may avoid salivary gland damage
11. Genetic predictor of breast cancer response to chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Age, Other Illnesses May Make Prostate Cancer Treatment Unnecessary
(Date:10/12/2017)... ... 12, 2017 , ... First Healthcare Compliance (FHC), an industry ... a range of technology and learning solutions at the 68th Annual American Healthcare ... be held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned ... Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness ... on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a ... today announced that its MyDario product is expected to appear on The ... when The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz ... The ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
(Date:9/19/2017)... -- HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy ... team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D ...
Breaking Medicine Technology: